YOKNEAM, Israel, Aug. 1, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the following investor conferences and events in August:
Canaccord Genuity's 43rd Annual Growth Conference
Presenters: Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: In-person fireside chat moderated by Kyle Rose, Senior Equity Analyst, and one-on-one meetings
Location: Boston, MA
When: Wednesday, Aug. 9 at 12:30 pm ET
A live webcast of the presentation can be accessed here.
Needham Virtual MedTech & Diagnostics 1x1 Conference
Presenters: Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: Virtual one-on-one meetings
When: Monday, Aug. 14
UBS Med Device Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Analyst, and one-on-one meetings
Location: Dana Point, CA
When: Tuesday, Aug. 15 at 9:00 am PT
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
| Last Trade: | US$14.35 |
| Daily Change: | 0.11 0.77 |
| Daily Volume: | 139,923 |
| Market Cap: | US$907.060M |
November 05, 2025 November 03, 2025 September 02, 2025 July 30, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
